Login to Your Account

Pharma: Other News To Note

Tuesday, June 26, 2012

• Janssen-Cilag International NV, of Beerse, Belgium, said the Committee for Medical Products for Human Use of the European Medicines Agency (EMA) recommended approval of subcutaneous administration of Velcade (bortezomib), indicated for multiple myeloma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription